Beacle, Inc.

Japan Science and Technology Agency

Suntory Limited

Masakazu Ueda

Akihiko Kondo

Masaharu Seno

Katsuyuki Tanizawa

Shunichi Kuroda

Toshihide Okajima

Shun'ichi Kuroda

The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody). The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.

Hollow nanoparticle of NBsAg large protein for drug delivery

As a versatile means for specifically and safely transporting and transferring substances (genes, proteins, compounds, etc.) into target cells and tissues, hollow nano particles comprising a protein capable of forming particles (e.g., hepatitis B virus surface antigen protein), and a biorecognition molecule introduced therein, are provided.

Hollow protein nano-particles and method of introducing substances into cells

The improved pharmaceutical composition for the treatment of adult respiratory distress syndrome (ARDS) contains a human atrial natriuretic peptide as an effective ingredient. It will combat ARDS against which no therapeutics have been found effective.

Pharmaceutical composition for treatment of adult respiratory distress

Growing community of inventors

Tokyo, Japan

Masakazu Ueda